Periodic Reporting for period 1 - EXACT-dna (EXtended Analysis of Circulating Tumour DNA to improve cancer management strategies)
Reporting period: 2017-12-01 to 2018-05-31
The objective of the Phase 1 project was to work out a business plan for the further clinical development and commercialization of our solutions.
The feasibility study has confirmed that there is a clear business opportunity to exploit on the global liquid biopsy market and to deliver new unique technologies for the isolation, detection and quantification of ctDNA.
IBSAFE™ and KROMA™ form a complete solution which is minimally invasive and simple when it comes to sample collection and is at least 100-fold more sensitive than competitors’ methods, having an industry leading 0.001% lower limit of detection. This translates into unique opportunities to detect clinically-actionable mutations and resistance mutations, aid treatment decisions, monitor drug response, predict good or poor survival and detect metastatic cancer years earlier compared to existing methods. We will deliver tools that will allow for a personalized approach to cancer management based on minimally invasive technologies that will shorten time to diagnosis and the treatment of patients and increase their comfort by reducing overtreatment